Neutra Corp Expands Clinical Research Footprint with New Family Medicine Trial Site

Neutra Corp (OTC: NTRR) announced that its wholly owned subsidiary, Neutra Life Sciences, has expanded its clinical research footprint by securing a new clinical trial site, MediNet Family Care Clinic, which specializes in Internal Medicine and Family Medicine. This strategic move aligns with the company's ongoing mission to grow its site management organization and bring high-quality, community-based research opportunities to diverse patient populations. Located in a high-traffic area near the border of Sugar Land and Houston, this Internal Medicine and Family Medicine site is led by an experienced research team with a strong background in conducting clinical trials and delivering consistent, quality data.

The site is fully equipped to support a wide range of protocol designs, including Phase II and III studies focused on chronic conditions such as hypertension, diabetes, hyperlipidemia, and other prevalent therapeutic areas. Sydney Jim, CEO of Neutra Corp, stated that this new partnership represents another important step in the company's long-term strategy to grow organically and provide sponsors and contract research organizations with efficient, responsive, and high-performing research sites. By expanding into Internal Medicine and Family Medicine, Neutra Life Sciences is furthering its ability to support diverse protocols while continuing to meet the highest standards of patient care and data integrity.

Concurrently, the company has engaged a dedicated Investor Relations Firm to strengthen communication and transparency with shareholders and the broader investment community. This strategic move underscores the company's commitment to building lasting investor confidence, enhancing market visibility, and providing timely, accurate insights into the company's growth, performance, and strategic direction. Neutra Life Sciences continues to experience steady growth across multiple specialties, with plans to add additional therapeutic areas in the coming quarters. Each new site is carefully selected and supported to ensure optimal performance and alignment with sponsor and contract research organization expectations.

With this expansion, Neutra Life Sciences is preparing to launch a new Diabetic Foot Ulcer trial at one of its brand-new sites in Sugar Land, Texas. The company maintains its corporate information at https://www.neutrainc.com while the original release can be viewed on https://www.newmediawire.com. This expansion into family medicine represents a significant step in making clinical trials more accessible to diverse patient populations and supporting research across multiple chronic conditions that affect millions of patients nationwide.